Your session is about to expire
← Back to Search
Anti-viral
Study to Compare Efficacy of Topical ARYS-01 (Sorivudine) Cream 3%, Oral Valaciclovir and Combination ARYS-01 Cream 3%/Oral Valaciclovir for Treatment of Herpes Zoster (Shingles)
Phase 2
Waitlist Available
Research Sponsored by aRigen Pharmaceuticals, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Summary
A multi-center, randomized, 4-arm, placebo-controlled, double-blind efficacy study of ARYS-01 (sorivudine) cream 3%.
Eligible Conditions
- Shingles
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Trial Design
4Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: 4Experimental Treatment2 Interventions
Active cream BID for 10 days and active valaciclovir caplets TID from days 1-10
Group II: 3Experimental Treatment3 Interventions
Active cream BID for 10 days and placebo valaciclovir caplets TID from days 1-3 and active valaciclovir caplets 1 gram TID from days 4-10
Group III: 2Active Control3 Interventions
Placebo cream BID for 10 days and active valaciclovir caplets TID from days 1-10
Group IV: 1Placebo Group2 Interventions
Placebo cream BID for 10 days and placebo valaciclovir caplets TID from days 1-3 and active valaciclovir caplets 1 gram TID from days 4-10
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
placebo
2010
Completed Phase 4
~6580
Valaciclovir
FDA approved
Find a Location
Who is running the clinical trial?
aRigen Pharmaceuticals, Inc.Lead Sponsor